The stock of Diurnal Group PLC (LON:DNL) hit a new 52-week low and has GBX 108.36 target or 14.00% below today’s GBX 126.00 share price. The 6 months bearish chart indicates high risk for the GBX 66.16M company. The 1-year low was reported on Nov, 4 by Barchart.com. If the GBX 108.36 price target is reached, the company will be worth GBX 9.26 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 3.82% or GBX 5 on November 4, hitting GBX 126. About 17,210 shares traded hands or 342.76% up from the average. Diurnal Group PLC (LON:DNL) has declined 14.29% since April 7, 2016 and is downtrending. It has underperformed by 15.38% the S&P500.
Another recent and important Diurnal Group PLC (LON:DNL) news was published by Bioworld.com which published an article titled: “Diurnal raises $44.7M, lists on AIM, awaits Infacort phase III readout in 3rd …” on December 22, 2015.
Diurnal Group plc is a United Kingdom specialty pharmaceutical company. The company has a market cap of 66.16 million GBP. The Firm targets patient needs in chronic endocrine diseases, such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. It currently has negative earnings. The Firm has two products in late-stage clinical development targeting adrenal disease: Chronocort and Infacort.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.